{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:36:58Z","timestamp":1792525018990,"version":"4.5.0"},"reference-count":32,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2025,7,3]]},"DOI":"10.1080\/10428194.2025.2482132","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T19:23:58Z","timestamp":1742757838000},"page":"1400-1412","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma"],"prefix":"10.1080","volume":"66","author":[{"given":"Nitin","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"Churchill Cancer Center, Oxford University Hospitals NHS Foundation Trust","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Winfree","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-8021","authenticated-orcid":false,"given":"Naleen Raj","family":"Bhandari","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Khanal","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Sugihara","sequence":"additional","affiliation":[{"name":"FSP Biometrics, Syneos Health","place":["Morrisville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Chen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Abada","sequence":"additional","affiliation":[{"name":"Loxo@Lilly","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-098X","authenticated-orcid":false,"given":"Krish","family":"Patel","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute","place":["Seattle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00595-6"},{"key":"e_1_3_5_3_1","volume-title":"StatPearls [Internet]","author":"Mukkamalla SKR","year":"2024","unstructured":"Mukkamalla SKR, Taneja A, Malipeddi D, et\u00a0al. Chronic lymphocytic leukemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. 2023 Mar 7. Retrieved from Chronic Lymphocytic Leukemia - StatPearls - NCBI Bookshelf. Cited on 11 December 2024."},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0018"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102468"},{"key":"e_1_3_5_6_1","article-title":"[internet] NCCN recommends zanubrutinib as first-line, second-line therapy in CLL, SLL","author":"Gavidia M.","year":"2020","unstructured":"Gavidia M. [internet] NCCN recommends zanubrutinib as first-line, second-line therapy in CLL, SLL. Am J Manag Care. 2020; Accessed from NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL, SLL Cited on 11 December 2024.","journal-title":"Am J Manag Care"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18075"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01056-1"},{"key":"e_1_3_5_9_1","unstructured":"FDA. [internet] FDA Approves Bristol Myers Squibb\u2019s Breyanzi\u00ae as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Available from BREYANZI (lisocabtagene maraleucel) | FDA. Cited on 11 December 2024."},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00070-6"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185741"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad324"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2190436"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.09.007"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000407"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.024224"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2001.09765"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.16.20037143"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes14122182"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2374041"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106629"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12589-9"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2348440"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179198"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx031"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011327"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15802"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198147"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194748"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-193673"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2025.2482132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:03:18Z","timestamp":1763467398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2025.2482132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7,3]]}},"alternative-id":["10.1080\/10428194.2025.2482132"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2025.2482132","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}